Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMC426
- Development stage
- Preclinical
- Lead developer
- Biomica
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
BMC426 is a preclinical, microbiome-based therapeutic candidate being developed by Biomica, a subsidiary of Evogene. [4] It is formulated as a Live Bacterial Product (LBP), which consists of a rationally designed consortium of four live bacterial strains. [2, 6] The strains were selected for their ability to address gut dysbiosis and are intended to provide therapeutic effects through metabolic and immune modulation. [1, 2, 6] BMC426 is being investigated for the treatment of Irritable Bowel Syndrome (IBS), with a focus on alleviating visceral pain. [1, 3, 6] Preclinical in-vivo studies have shown that treatment with BMC426 significantly reduced visceral sensitivity in animal models compared to placebo. [2] The development of BMC426 utilizes Biomica's proprietary PRISM computational platform, which is powered by Evogene's MicroBoost AI technology, to analyze data from IBS patients and design the bacterial consortium. [2, 6]
Beyond the preview
Go deeper on BMC426.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMC426.